Welcome to our dedicated page for AURORA CANNABIS SEC filings (Ticker: ACB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aurora Cannabis Inc. filings document its U.S. reporting as a Canadian foreign private issuer and the formal disclosure record for its medical cannabis operations. Recent Form 6-K reports furnish news releases, material change reports, sales agreements and offering documents tied to product launches, financial results, acquisitions, governance matters and capital-structure activity.
The filings include disclosure for an at-the-market common-share program under shelf registration documents, material change reports on corporate transactions, and exhibits incorporated by reference into Form F-10 and Form S-8 registration statements. They also record Aurora's operating updates across regulated cannabis markets, GMP-certified manufacturing network, shareholder voting matters and executive-level governance disclosures.
AURORA CANNABIS INC (symbol: ACB) is the issuer of record for a Form 6-K filing submitted to the SEC.
Aurora Cannabis Inc. (ACB) reports that Curaleaf Holdings, Inc. has formally commenced an unsolicited take-over bid for all issued and outstanding Aurora common shares. The bid offers implied consideration of US$4.00 per Aurora share, composed of 0.3463 Curaleaf subordinate voting share plus US$0.75 in cash per Aurora share, and includes a value cap of US$5.00 per share.
Aurora states that this cap is below the trading price of Aurora shares on December 18, 2025. The board has formed a Special Committee of independent directors to review the bid with its legal and financial advisors before making a recommendation. The offer must remain open for at least 105 days, giving shareholders until at least December 1, 2026 to assess their options.
Aurora advises shareholders to take no action on the offer until the board issues its formal recommendation, which will be communicated via a news release and Directors’ Circular within 15 days of the bid, in line with applicable securities laws. Kingsdale Advisors is acting as strategic advisor and information agent and is available to answer shareholder questions.
Aurora Cannabis Inc. reports that Curaleaf Holdings has stated an intention to launch an unsolicited take-over bid for all outstanding Aurora common shares. Curaleaf’s indicated Proposal implies US$4.00 per Aurora share, made up of 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash, and includes a value cap of US$5.00 per share.
Aurora confirms receiving acquisition proposal letters from Curaleaf dated June 23 and July 7, 2026 and states the Proposal was not initiated or solicited by Aurora. The Board plans to form a special committee of independent directors to review the Proposal alongside Aurora’s strategic alternatives, including its recently completed acquisition of Safari Flower Company and expanding EU‑GMP cultivation and manufacturing capacity. No decision has been made, there is no assurance any transaction will occur, and Aurora continues to operate business as usual. Aurora states that shareholders do not need to take any action at this time.
Aurora Cannabis Inc. reports that Curaleaf Holdings has stated an intention to launch an unsolicited take-over bid for all Aurora common shares. The stated implied consideration is US$4.00 per share, consisting of 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash per Aurora share, subject to a US$5.00 per-share value cap.
Aurora confirms receiving acquisition proposal letters from Curaleaf dated June 23, 2026 and July 7, 2026, and states that the July 7 letter was the first to include proposed financial terms. Aurora highlights its recently completed acquisition of Safari Flower Company and its growing EU-GMP cultivation and manufacturing capacity as part of its strategic plan.
The Board plans to form a special committee of independent directors to evaluate the Proposal alongside other strategic alternatives. Aurora states that no decision has been made, there is no assurance any transaction will occur, and operations and strategic execution are continuing as usual. Shareholders are told they do not need to take any action at this time.
Aurora Cannabis Inc. reported the results of its August 7, 2026 annual general meeting of shareholders. At the record date of June 15, 2026, there were 61,956,924 common shares outstanding, with 16,639,306 shares represented in person or by proxy, equal to 26.86% of outstanding shares.
Shareholders approved fixing the number of directors at five, with 91.65% of votes cast in favor. All director nominees were elected, including Miguel Martin, Michael Singer, Chitwant Kohli, Norma Beauchamp, and Rajesh Uttamchandani, each receiving between roughly 85–87% of votes cast "for" and about 13–15% withheld.
Ernst & Young LLP was appointed as independent auditor until the next annual meeting, with 92.81% of votes cast in favor and 7.19% withheld. Shareholders also passed the non-binding say-on-pay advisory resolution on the company’s approach to executive compensation, with 82.97% support and 17.03% against.
Aurora Cannabis Inc. reported the results of its 2026 Annual General Meeting of Shareholders, held by virtual webcast on August 7, 2026. Shareholders represented 16,639,306 common shares, equal to 26.86% of issued and outstanding shares as of the record date.
All five board nominees were elected, each receiving more than 85% of votes cast, including CEO Miguel Martin with 5,076,096 votes for and 85.12% support. Shareholders also approved the appointment of Ernst & Young LLP as auditors for the ensuing year. The advisory vote on executive compensation (Say‑on‑Pay) passed with 82.97% of votes for. Aurora states that the voting outcomes support its medical‑first strategy and ongoing focus on its global medical cannabis business.
Aurora Cannabis reported fiscal 2027 first‑quarter net revenue of $67.6 million, down 9% from $74.1 million a year earlier, mainly from lower Canadian medical revenue and the wind down of consumer cannabis, partly offset by higher international medical and wholesale bulk sales. Adjusted gross margin before fair value adjustments on total revenue was 58%, down from 64%.
Medical cannabis net revenue was $64.0 million, with Canadian medical declining 25% to $20.7 million after federal reimbursement cuts, while international medical rose 17% to $43.3 million on higher German demand. Consumer cannabis revenue fell to $2.1 million as the company exits this business.
Net loss from continuing operations narrowed to $4.0 million from $10.2 million, but adjusted EBITDA decreased to $3.4 million from $10.8 million and free cash flow moved to an outflow of $5.8 million from an inflow of $6.8 million. Working capital was $320.0 million. Aurora completed the Safari Flower Company acquisition, adding a 59,000 square foot EU‑GMP certified facility with planned growth capex of about $3.5 million. The company reiterates its full‑year 2027 outlook and states it expects fiscal Q2 revenue and adjusted EBITDA to be sequentially higher.
Aurora Cannabis Inc. reported results for the three months ended June 30, 2026, as it refocuses on higher-margin global medical cannabis. Net revenue was C$67.6 million, down from C$74.1 million a year earlier, while net loss from continuing operations narrowed to C$4.0 million from C$10.2 million.
Medical cannabis net revenue was stable at C$64.0 million: Canadian medical declined to C$20.7 million after an estimated 30% cut to federal reimbursement rates, offset by international medical growth to C$43.3 million, mainly in Germany. Consumer cannabis revenue fell to C$2.1 million as that business is wound down.
Gross margin before fair value adjustments fell to 43%, but reported gross margin rose to 53% on higher fair value gains from biological assets. Adjusted EBITDA was C$3.4 million versus C$10.8 million, and free cash flow was an outflow of C$5.8 million.
The company acquired Safari Flower Company for total consideration of about C$24.7 million, adding EU-GMP-certified capacity that contributed C$2.8 million of revenue and C$1.7 million of pre-tax profit in the period. Liquidity comprised C$69.3 million of cash, C$30.7 million of short-term investments and restricted cash, including about C$46.4 million expected to be released after winding up a segregated cell insurance program.
Aurora Cannabis Inc. reports that Institutional Shareholder Services Inc. (ISS), a leading independent proxy advisory firm, has recommended that shareholders vote FOR all resolutions described in Aurora’s management information circular for the 2026 Annual General Meeting of Shareholders.
The AGM will be held as a virtual-only meeting on August 7, 2026 at 1:00 p.m. Eastern time, accessible via live webcast. The deadline for shareholders to vote their shares is 1:00 p.m. Eastern time on August 5, 2026. Aurora has engaged Kingsdale Advisors to provide shareholder questions and voting assistance and highlights its focus on global medical cannabis markets and long-term value creation.